Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

11.35 EUR

-0.87 %

5,624 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-0.87 %
-9.56 %
-20.07 %
-20.07 %
-14.66 %
+25.00 %
+190.28 %
+48.23 %
-98.13 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
81.87M EUR
Turnover
110.19K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Reduce
Target price
Updated
05.01.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 05.01.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2.
2026

Annual report '25

30.3.
2026

General meeting '26

14.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Nexstim’s NBS 6 system receives MDR certification in the EU for use in Post-Operative Rehabilitation Press release, Helsinki, 19 February 2026 at 9 AM (EET) Nexstim’s NBS 6 system receives MDR certification in the EU for use in Post-Operative Rehabilitation Nexstim Plc (“Nexstim”...
2/19/2026, 7:08 AM
by Kyhnykeisari
45
Provider Newsroom – 6 Feb 26 TMS prior authorization requirement to be removed for contracted providers -... Evernorth® Behavioral Health (Evernorth) is pleased to announce that effective March 6, 2026, prior authorization will [...]Read now Est. reading time: 2 minutes The adoption...
2/18/2026, 2:16 PM
by Kyhnykeisari
34
This is indeed very good news. There is already a significant number of NBS 5 hardware systems globally, and this provides a strong impetus for upgrading them to the 6th generation. For the 6-series units already sold, software is being sold in turn = high-margin business. Great ...
2/19/2026, 7:39 AM
by Kyhnykeisari
26
https://x.com/nexstimoyj/status/2024378935832613151?s=46&t=DJpQdxgjvhxjIaUum88HeQ nexstim.com Nexstim - Press-release
2/19/2026, 7:02 AM
by Mark_Renton
26
Looking through rose-tinted glasses: I wonder if a backlog for NBS6 sales has already built up in the UAE, which Brainlab can now start clearing? In my previous job, I dealt with customers from that region to some extent, and there is a very strong phenomenon where you have to get...
2/17/2026, 6:52 AM
by Mark_Renton
24
This new certification will presumably also increase the amount of guaranteed sales margin. Naturally, it has no impact on the share price, as is the case with any other particularly good news regarding Nexstim.
yesterday
by Kyhnykeisari
18
A quick look at some figures (so there may be errors): In Europe, an estimated 82,000 – 85,000 new brain tumors or central nervous system tumors are diagnosed annually. It is difficult to provide an exact, continent-wide figure for the number of resected (operated) tumors, as not...
2/19/2026, 7:53 AM
by AccionHombre
16
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.